ReviewStem cells international2018
Cardiac Progenitor Cells in Basic Biology and Regenerative Medicine.
Review in Stem cells international, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Cardiac Circular RNAs CDR1as, Circ-RCAN2, Circ-C12orf29 Show Cell-Specific Hypoxia-Induced Dysregulation and Distinct In Vitro Effects.International journal of molecular sciences · 2025Article
- Current status and new horizons in stem cell therapy in cardiovascular regenerative medicine (CaVaReM): an update.European journal of medical research · 2025Review
- An overview on cardiac regeneration revolution: exploring the promise of stem cell therapies.Molecular biology reports · 2025Review
- Cardiopulmonary progenitors facilitate cardiac repair via exosomal transfer of miR-27b-3p targeting the SIK1-CREB1 axis.Cell proliferation · 2024Article
- Article
- Cardiac stem cells: Current knowledge and future prospects.World journal of stem cells · 2022Review
- Pioglitazone Mediates Cardiac Progenitor Formation through Increasing ROS Levels.BioMed research international · 2022Article
- Highlighting Exosomes' Function in Cardiovascular Diseases.Current cardiology reviews · 2022Article
- A New Role for Extracellular Vesicles in Cardiac Tissue Engineering and Regenerative Medicine.Advanced nanobiomed research · 2021Article
- Roles Played by YY1 in Embryonic, Adult and Cancer Stem Cells.Stem cell reviews and reports · 2021Review
- Cell Sheet Comprised of Mesenchymal Stromal Cells Overexpressing Stem Cell Factor Promotes Epicardium Activation and Heart Function Improvement in a Rat Model of Myocardium Infarction.International journal of molecular sciences · 2020Article
- Strategies and Challenges to Improve Cellular Programming-Based Approaches for Heart Regeneration Therapy.International journal of molecular sciences · 2020Review
- Transplantation of hMSCs Genome Edited with LEF1 Improves Cardio-Protective Effects in Myocardial Infarction.Molecular therapy. Nucleic acids · 2020Article
- Building an Artificial Cardiac Microenvironment: A Focus on the Extracellular Matrix.Frontiers in cell and developmental biology · 2020Review
- Toward Cardiac Regeneration: Combination of Pluripotent Stem Cell-Based Therapies and Bioengineering Strategies.Frontiers in bioengineering and biotechnology · 2020Review
- Review
- Safety profiling of genetically engineered Pim-1 kinase overexpression for oncogenicity risk in human c-kit+ cardiac interstitial cells.Gene therapy · 2019Article
- Combination of Cardiac Progenitor Cells From the Right Atrium and Left Ventricle Exhibits Synergistic Paracrine Effects In Vitro.Cell transplantationArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Major cardiovascular events including myocardial infarction (MI) continue to dominate morbidity rates in the developed world. Although multiple device therapies and various pharmacological agents have been shown to improve patient care and reduce mortality rates, clinicians and researchers alike still lack a true panacea to regenerate damaged cardiac tissue. Over the previous two to three decades, cardiovascular stem cell therapies have held great promise. Several stem cell-based approaches have now been shown to improve ventricular function and are documented in preclinical animal models as well as phase I and phase II clinical trials. More recently, the cardiac progenitor cell has begun to gain momentum as an ideal candidate for stem cell therapy in heart disease. Here, we will highlight the most recent advances in cardiac stem/progenitor cell biology in regard to both the basics and applied settings.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.